mHSPC VL

mHSPC Network Meta-Analysis on the Use of Intensified Treatments - Fred Saad

Details
Fred Saad joins Alicia Morgans to discuss his recently published network meta-analysis on treatments for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Saad and his team put together a network meta-analysis focusing on 11 randomized controlled trials to determine the best approach for patients with mHSPC. The triplet of androgen deprivation therapy (ADT), androgen receptor...

Treatment Intensification in Metastatic Castrate-Sensitive Prostate Cancer - Christopher Wallis & Zachary Klaassen

Details
In this discussion, Zachary Klaassen and Christopher Wallis discuss treatment intensification in metastatic castrate-sensitive prostate cancer (mCSPC). Dr. Klaassen and Dr. Wallis focus their discussion on several studies in the United States and across the globe that have looked at the real-world utilization of androgen deprivation therapy (ADT) plus other agents in the mCSPC disease space. Drs....

Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg

Details
In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive stage....

mCSPC Couplet vs Triplet Therapy LUGPA 2022 Presentation - Alicia Morgans

Details
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022: Treatment...

Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay

Details
Rana McKay and Alicia Morgans discuss the CYCLONE 3 trial in progress in high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Recent data from the ARASENS trial shows a survival benefit for treatment intensification with ADT + docetaxel + a novel hormonal agent, triplet therapy, vs ADT + docetaxel in selected patients. Yet, there is a significant medical need to expand therapeutic optio...

The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz

Details
Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification. In highlighting these studies outlines the following 5 key questions for the field of mHSPC: Do all patients with mHSPC benefit from ADT intensification? When should we use triplet (ADT + ARSI + docetax...

8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam

Details
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable level...

The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore

Details
Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...

APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu discusses the changing landscape of metastatic hormone-sensitive prostate cancer treatment with Alicia Morgans. Dr. Yu provides an overview of the many important questions and concerns clinicians must address in sequencing treatment for mCRPC patients in light of novel hormone therapy agents and the opportunity for triplet therapy. Biographies: Evan Yu, MD , Professor, Department of Medici...

(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT - Charles Ryan

Details
In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the (AF...
email news signup